Trials / Completed
CompletedNCT00105521
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 398 (actual)
- Sponsor
- EMD Serono · Industry
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test multiple doses of sarizotan to establish a dose with maximal safety and efficacy for treating treatment associated dyskinesia in Parkinson's disease participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sarizotan | Sarizotan will be administered twice daily. |
| DRUG | Placebo | Placebo matching to sarizotan will be administered twice daily. |
Timeline
- Start date
- 2004-09-30
- Primary completion
- 2006-03-31
- Completion
- 2006-03-31
- First posted
- 2005-03-16
- Last updated
- 2018-04-02
- Results posted
- 2018-04-02
Locations
32 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00105521. Inclusion in this directory is not an endorsement.